Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study to Evaluate the Safety and Efficacy of EOS100850 as a Single Agent and in Combination with KEYTRUDA (Pembrolizumab) in Patients with Several Solid Tumor Indications

Next Previous
Trial Profile

A Phase I/II Study to Evaluate the Safety and Efficacy of EOS100850 as a Single Agent and in Combination with KEYTRUDA (Pembrolizumab) in Patients with Several Solid Tumor Indications

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inupadenant (Primary) ; Pembrolizumab (Primary)
  • Indications Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 14 Jun 2021 According to a GlaxoSmithKline media release, preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker.
  • 13 May 2021 According to an iTeos Therapeutics media release, the initial cohort is evaluating inupadenant as a monotherapy in prostate cancer, and the second cohort is evaluating the safety of inupadenant in combination with pembrolizumab in patients with solid tumors with planned expansions in prostate cancer and melanoma. The final cohort is evaluating inupadenant in combination with chemotherapy in patients with triple-negative breast cancer.
  • 12 Nov 2020 According to an iTeos Therapeutics media release, in addition to the single-agent cohort, dosing has also commenced in the second cohort evaluating EOS-850 in combination with pembrolizumab. The COVID-19 pandemic has resulted in the Company experiencing enrollment delays for its third cohort evaluating EOS-850 in combination with chemotherapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top